T 0466/23 (Liquid adalimumab pharmaceutical composition / FRESENIUS) of 20.06.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T046623.20240620
- Date of decision
- 20 June 2024
- Case number
- T 0466/23
- Petition for review of
- -
- Application number
- 15723695.1
- IPC class
- A61K 9/00
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- LIQUID PHARMACEUTICAL COMPOSITION
- Applicant name
- Fresenius Kabi Deutschland GmbH
- Opponent name
- Biogen Inc.
Samsung Bioepis NL B.V. - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 100(c)European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56
- Keywords
- Grounds for opposition - extension of subject-matter (no)
Novelty - (yes)
Inventive step - (yes) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed.